Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. (NASDAQ: CRIS) is a biotechnology company dedicated to the development and commercialization of groundbreaking drug candidates aimed at treating human cancers. Established as a significant player in the biotech sector, Curis is renowned for its focus on immuno-oncology and precision oncology therapeutic areas.
Core Business and Pipeline
Curis's pipeline is robust, featuring a number of promising drug candidates. One of its leading drugs is Emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor currently undergoing clinical trials. The trials include the Phase 1/2 TakeAim Lymphoma study, which targets hematologic malignancies such as non-Hodgkin's lymphoma, and the Phase 1/2 TakeAim Leukemia study aimed at acute myeloid leukemia and myelodysplastic syndrome. Emavusertib has already received Orphan Drug Designation from the U.S. Food and Drug Administration.
Curis is also investigating other candidates such as CUDC-907, which focuses on relapsed or refractory diffuse large B-cell lymphoma with alterations in the MYC oncogene, and other small molecule antagonists like CA-170 and CA-327, designed to inhibit pathways such as PD1, VISTA, and TIM3.
Collaborations & Partnerships
Curis has forged a strategic collaboration with Aurigene, granting it exclusive licenses to several promising molecules. This partnership enhances Curis's ability to innovate in the areas of immuno-oncology and precision oncology, specifically with oral small molecule antagonists. Additionally, Curis has licensed its rights to Erivedge® to Genentech, which is commercializing the drug for advanced basal cell carcinoma under the Roche Group.
Recent Achievements and Financial Condition
Curis has recently presented data from multiple clinical studies at prestigious conferences such as the American Society of Hematology (ASH) and the European Hematology Association (EHA), showcasing promising results from its ongoing trials. The company reported a net loss of $47.4 million for the year ended December 31, 2023, but continues to maintain a strong cash position with $56.3 million in cash, cash equivalents, and investments.
Curis's ongoing research and development efforts are backed by substantial funding and strategic partnerships, enabling the company to sustain its operations and advance its pipeline into the year 2025.
For more information, visit Curis's website at www.curis.com.
Curis, Inc. (NASDAQ: CRIS) announced that on March 31, 2023, its independent Compensation Committee approved an inducement stock option grant for 135,450 shares to a new employee. The stock options have a ten-year term, an exercise price equal to the stock's closing price on the grant date, and will vest over four years. The vesting schedule includes 25% after the first anniversary and an additional 6.25% every three months thereafter, contingent on continued service. This grant is part of Curis's strategy to attract and retain talent as it continues to develop innovative cancer therapies.
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, announced participation in two upcoming virtual conferences. The Cantor Fitzgerald Future of Oncology Symposium will be held from April 3 to 5, 2023, with a panel presentation on April 5 at 12:00 PM ET. The 22nd Annual Needham Virtual Healthcare Conference is set for April 17 to 20, 2023, featuring Curis on April 20 at 2:15 PM ET. Curis is recognized for its collaborations in immuno-oncology and precision oncology, with ongoing trials for its candidate emavusertib and commercial partnerships for Erivedge®.
Curis, Inc. (NASDAQ: CRIS) has successfully completed enrollment of 9 additional patients in its TakeAim Leukemia study ahead of schedule, addressing the FDA's requirements to resolve a partial clinical hold. Data from these patients is anticipated in Q2 2023, with discussions planned with the FDA for Q3 regarding the recommended Phase 2 dose for emavusertib, an IRAK-4 inhibitor. Financially, Curis reported a net loss of $56.7 million for 2022, with revenues slightly down to $10.2 million compared to the prior year. As of December 31, 2022, the company holds $85.6 million in cash, expected to fund operations into 2025.
Curis, Inc. (NASDAQ: CRIS) has announced the rescheduling of its fourth quarter business update and investor conference call from March 9, 2023, to March 13, 2023. The update will be released at 8:00 a.m. ET, followed by the conference call at 8:30 a.m. ET. To access the call, investors can dial (888)-346-6389 or (412)-317-5252 for international calls, or join via the Curis website. The company focuses on innovative cancer therapeutics, collaborating with partners like Aurigene and Genentech, currently testing drug candidates in various trials, including a Phase 1/2 trial for its IRAK4 inhibitor, emavusertib.
FAQ
What is the current stock price of Curis (CRIS)?
What is the market cap of Curis (CRIS)?
What is Curis Inc.'s focus in the biotechnology sector?
What are some of the key drug candidates in Curis's pipeline?
What significant collaborations does Curis have?
What is the current status of Emavusertib's clinical trials?
How is Curis performing financially?
What recent achievements has Curis reported?
What is the significance of Curis's collaboration with Aurigene?
What role does Genentech play in Curis's portfolio?
What are Curis's future plans for its drug pipeline?
Where can I find more information about Curis Inc.?
